Vident Investment Advisory LLC Takes Position in Zymeworks Inc (ZYME)

Share on StockTwits

Vident Investment Advisory LLC bought a new position in Zymeworks Inc (NYSE:ZYME) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 151,791 shares of the company’s stock, valued at approximately $2,243,000. Vident Investment Advisory LLC owned 0.48% of Zymeworks as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZYME. Cubist Systematic Strategies LLC purchased a new position in Zymeworks during the 2nd quarter valued at $101,000. Raymond James & Associates purchased a new position in Zymeworks during the 2nd quarter valued at $578,000. Point72 Asset Management L.P. purchased a new position in Zymeworks during the 2nd quarter valued at $1,478,000. Laurion Capital Management LP purchased a new position in Zymeworks during the 2nd quarter valued at $1,612,000. Finally, Wedge Capital Management L L P NC purchased a new position in Zymeworks during the 2nd quarter valued at $2,162,000. 25.07% of the stock is currently owned by institutional investors.

A number of research analysts have issued reports on ZYME shares. Citigroup downgraded shares of Zymeworks from a “buy” rating to a “neutral” rating in a research report on Wednesday, June 6th. Raymond James boosted their price objective on shares of Zymeworks from $22.00 to $27.00 and gave the company an “outperform” rating in a research report on Tuesday, June 5th. Canaccord Genuity set a $21.00 price objective on shares of Zymeworks and gave the company a “buy” rating in a research report on Wednesday, September 5th. ValuEngine raised shares of Zymeworks from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Wells Fargo & Co boosted their price objective on shares of Zymeworks from $20.00 to $37.00 and gave the company an “outperform” rating in a research report on Monday, June 4th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $21.68.

In other news, major shareholder Eli & Co Lilly sold 19,400 shares of the business’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $13.31, for a total transaction of $258,214.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 78,317 shares of company stock worth $1,113,895.

Shares of ZYME stock opened at $14.66 on Friday. Zymeworks Inc has a 12 month low of $6.87 and a 12 month high of $29.00.

Zymeworks (NYSE:ZYME) last announced its earnings results on Wednesday, August 1st. The company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.36. Zymeworks had a negative net margin of 14.66% and a negative return on equity of 8.83%. The firm had revenue of $22.00 million for the quarter, compared to analysts’ expectations of $22.00 million. research analysts expect that Zymeworks Inc will post -2.42 earnings per share for the current year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer.

Read More: What is the Dow Jones Industrial Average (DJIA)?

Institutional Ownership by Quarter for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Vanguard S&P 500 ETF  Shares Bought by Zacks Investment Management
Vanguard S&P 500 ETF Shares Bought by Zacks Investment Management
Vident Investment Advisory LLC Takes Position in Zymeworks Inc
Vident Investment Advisory LLC Takes Position in Zymeworks Inc
Vident Investment Advisory LLC Has $2.37 Million Stake in Owens Corning
Vident Investment Advisory LLC Has $2.37 Million Stake in Owens Corning
Agrello  Hits Market Capitalization of $4.25 Million
Agrello Hits Market Capitalization of $4.25 Million
Debitum Price Reaches $0.0197
Debitum Price Reaches $0.0197
Legal & General Group Plc Acquires 15,398 Shares of Uniti Group Inc
Legal & General Group Plc Acquires 15,398 Shares of Uniti Group Inc


Leave a Reply

© 2006-2018 Ticker Report. Google+.